2114-S - Data Integrity Strategic Consulting

In support of the UK Government's emergency response to the Covid-19 variant concern. CPI have applied for a Manufacturing and Importation Authorisation for Investigational Medicinal Products (MIA(IMP)), to support delivery of Covid-19 variant vaccine for use in clinical trials. The UK regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA) will be inspecting our facility in order to achieve accreditation and one of the gaps identified during the pre-inspection risk assessment was the data integrity strategy and governance within CPI. The closure of this gap is integral to a positive inspection outcome and will allow CPI to support the UK Covid variant response.